Premium
Therapeutic potency of oncolytic virotherapy–induced cancer stem cells targeting in brain tumors, current status, and perspectives
Author(s) -
Bahreyni Amirhossein,
Ghorbani Elnaz,
Fuji Hamid,
Ryzhikov Mikhail,
Khazaei Majid,
Erfani Marjan,
Avan Amir,
Hassanian Seyed M.,
Azadmanesh Kayhan
Publication year - 2019
Publication title -
journal of cellular biochemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.028
H-Index - 165
eISSN - 1097-4644
pISSN - 0730-2312
DOI - 10.1002/jcb.27661
Subject(s) - oncolytic virus , virotherapy , potency , cancer research , cancer stem cell , stem cell , cancer therapy , medicine , cancer , brain cancer , oncology , tumor cells , biology , microbiology and biotechnology , genetics , in vitro
Brain tumors are the most common form of solid tumors in children and is presently a serious therapeutic challenge worldwide. Traditional treatment with chemotherapy and radiotherapy was shown to be unsuccessful in targeting brain tumor cancer stem cells (CSCs), leading to recurrent, treatment‐resistant secondary malignancies. Oncolytic virotherapy (OV) is an effective antitumor therapeutic strategy which offers a novel, targeted approach for eradicating pediatric brain tumor CSCs by utilizing mechanisms of cell killing that differ from conventional therapies. A number of studies and some clinical trials have therefore investigated the effects of combined therapy of radiations or chemotherapies with oncolytic viruses which provide new insights regarding the effectiveness and improvement of treatment responses for brain cancer patients. This review summarizes the current knowledge of the therapeutic potency of OVs‐induced CSCs targeting in the treatment of brain tumors for a better understanding and hence a better management of this disease.